Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM

Seulki Cho\textsuperscript{a,b}, Insoo Park\textsuperscript{c,*}, Haejung Kim\textsuperscript{b}, Mun Sik Jeong\textsuperscript{d}, Mooney Lim\textsuperscript{d}, Eung Suk Lee\textsuperscript{b,**}, Jin Hong Kim\textsuperscript{b}, Semi Kim\textsuperscript{c}, and Hyo Jeong Hong\textsuperscript{b,d}

\textsuperscript{a}Department of Functional Genomics, University of Science & Technology, Daejeon, Korea; \textsuperscript{b}Institute of Bioscience and Biotechnology, Kangwon National University, Chuncheon, Korea; \textsuperscript{c}Immunotherapy Research Center, Korea Research Institute of Bioscience & Biotechnology, Daejeon, Korea; \textsuperscript{d}Department of Systems Immunology, Kangwon National University, Chuncheon, Korea

ABSTRACT
L1 cell adhesion molecule (L1CAM) is aberrantly expressed in malignant tumors and plays important roles in tumor progression. Thus, L1CAM could serve as a therapeutic target and anti-L1CAM antibodies may have potential as anticancer agents. However, L1CAM is expressed in neural cells and the druggability of anti-L1CAM antibody must be validated at the earliest stages of preclinical study. Here, we generated a human monoclonal antibody that is cross-reactive with mouse L1CAM and evaluated its pharmacokinetic properties and anti-tumor efficacy in rodent models. First, we selected an antibody (Ab4) that binds human and mouse L1CAM from the human naive Fab library using phage display, then increased its affinity 45-fold through mutation of 3 residues in the complementarity-determining regions (CDRs) to generate Ab4M. Next, the affinity of Ab4M was increased 1.8-fold by yeast display of single-chain variable fragment containing randomly mutated light chain CDR3 to generate Ab417. The affinities (K_d) of Ab417 for human and mouse L1CAM were 0.24 nM and 79.16 pM, respectively. Ab417 specifically bound the Ig5 domain of L1CAM and did not exhibit off-target activity, but bound to the peripheral nerves embedded in normal human tissues as expected in immunohistochemical analysis. In a pharmacokinetics study, the mean half-life of Ab417 was 114.49 h when a single dose (10 mg/kg) was intravenously injected into SD rats. Ab417 significantly inhibited tumor growth in a human cholangiocarcinoma xenograft nude mouse model and did not induce any adverse effect in vivo studies. Thus, Ab417 may have potential as an anticancer agent.

Abbreviations: L1CAM, L1 cell adhesion molecule; mAb, monoclonal antibody; Ig, immunoglobulin; Fn, fibronectin; scFv, single-chain variable fragment; FACS, fluorescence-activated cell sorting; CDR, complementarity-determining region; Fab, fragment antigen-binding; K_d, dissociation constant; ELISA, enzyme-linked immunosorbent assay; MACS, magnetic-activated cell sorting; hFc, human IgG1 Fc; ECD, extracellular domain; Cy1, heavy chain constant region 1; Cl, light chain (kappa) constant region; PBS, phosphate-buffered saline; PBA, PBS containing BSA; VH, variable heavy chain; VL, variable light chain; TBST, tris-buffered saline containing Tween-20; IR, tumor growth inhibition rate; ANOVA, analysis of variance.

Introduction

L1 cell adhesion molecule (L1CAM, CD171) is a 200-220 kDa transmembrane glycoprotein consisting of 6 immunoglobulin (Ig)-like domains followed by 5 fibronectin-type III repeats, a transmembrane domain, and a short cytoplasmic tail.\textsuperscript{1} L1CAM was first described as a neural cell adhesion molecule and has been shown to initiate a variety of dynamic motile processes, including cerebellar cell migration and neurite outgrowth during central nervous system development.\textsuperscript{2} L1CAM is expressed to some extent in other normal cells, including lymphoid and myelomonocytic cells, kidney tubule epithelial cells, and intestinal crypt cells,\textsuperscript{3-5} but is aberrantly expressed in a variety of malignant tumors. The expression of L1CAM in tumors is associated with poor prognosis and metastasis.\textsuperscript{6} L1CAM promotes many cellular activities via homophilic interactions with its extracellular region\textsuperscript{7} and heterophilic interactions with other CAMs, extracellular matrix molecules, signaling receptors, and...
Monoclonal antibodies (mAbs) targeting tumor cells via growth factor receptors, such as HER2/neu or epidermal growth factor receptor, are clinically effective for the treatment of metastatic breast cancer or colorectal and head and neck cancers, respectively.\textsuperscript{25-28} In studies with anti-L1CAM mAbs, a murine mAb significantly reduced tumor growth in pancreatic and ovarian carcinoma xenograft models, whereas a chimeric antibody reduced tumor growth in a cholangiocarcinoma xenograft model.\textsuperscript{29-31} The results suggest that these anti-L1CAM mAbs have potential as anticancer agents for the treatment of cancer. However, the mAbs bind only to human L1CAM; thus, their pharmacokinetic and toxicological properties and therapeutic efficacy in mice models are different from those in humans. In addition, because L1CAM is expressed in neural cells and other normal cells, such as monocytes and kidney tubule epithelial cells, anti-L1CAM antibody use has safety concerns. Therefore, the generation of a mAb that cross-reacts with rodent L1CAM is necessary to validate its druggability in the earliest stages of antibody development.

In vitro technologies that display recombinant antibody libraries on the surface of phage or yeast have been used to produce antibodies with high affinity and specificity and to improve biophysical properties.\textsuperscript{32-34} Naive, immune, semi-synthetic, and synthetic antibody libraries have been constructed in single-chain variable fragment (scFv) or Fab format.\textsuperscript{35} The major advantages of phage display include application to a wide range of antigens, irrespective of their immunogenicity and toxicity, the isolation of cross-reactive antibodies for animal models, and the ability to fully control the selection conditions.\textsuperscript{36} Yeast display is more useful for affinity maturation than other in vitro display technologies, as it allows quantitative screening and compensation of the antigen-binding signal to expression signal during fluorescence-activated cell sorting (FACS).\textsuperscript{37}

Cholangiocarcinoma is a malignant tumor arising from the bile duct epithelium. The prognosis for cholangiocarcinoma is poor due to the lack of early diagnosis and because it is refractory to conventional chemotherapy and radiation therapy.\textsuperscript{38} A Phase 3 clinical trial in advanced biliary cancers reported significant prolongation of median overall survival when gemcitabine is combined with cisplatin compared to gemcitabine alone, establishing this combination as a global standard of care.\textsuperscript{39} However, the 5-year survival of cholangiocarcinoma remains low.\textsuperscript{40} Therefore, targeted therapies that improve patient survival are needed for patients with advanced biliary cancer. Previously, we found that L1CAM is aberrantly expressed in cholangiocarcinoma and plays an important role in tumor progression by enhancing cell proliferation, migration, apoptosis resistance, and tumor growth.\textsuperscript{18,19,22,41,42} Here, we isolated a human anti-L1CAM mAb that binds to human and mouse L1CAM from a human naïve Fab library using phage display and developed an affinity-matured antibody (Ab417) through site-directed mutagenesis of complementarity-determining regions (CDR) residues and yeast display of scFvs containing randomly mutated light chain CDR3. Subsequently, we evaluated the specificity, pharmacokinetic properties, and anti-tumor efficacy of Ab417 in rodent models.

**Results**

**Isolation of human Fabs binding human and mouse L1CAM from phage-displayed antibody library**

To isolate human mAbs that bind to both human and mouse L1CAM, a human naïve Fab library was screened by panning against the extracellular domains of human and mouse L1CAM. The first and second rounds of panning were performed against human L1CAM, and the third panning was performed against mouse L1CAM. Finally, 6 different cross-reactive Fab clones were obtained, with Ab4 Fab having the highest antigen binding activities to both human and mouse L1CAM. This clone was selected for further study. Ab4 Fab was converted to human IgG1 form (Ab4), expressed transiently in HEK293T cells, and then purified by affinity chromatography on a Protein A column. The affinity ($K_d$) of Ab4 for human L1CAM by competitive ELISA was approximately 100 nM (data not shown).

**Affinity maturation of Ab4 by site-directed mutagenesis**

For affinity maturation of Ab4, we performed alanine-scanning mutagenesis on the HCDR1, HCDR2, HCDR3, and LCDR3 residues to analyze the role of each residue in antigen binding. As shown in Fig. 1A, alanine mutation (H97A) of His97 in HCDR3 increased the antigen-binding activity for human and mouse L1CAM, whereas the mutation of other residues in HCDR1, HCDR2, and HCDR3 significantly decreased the binding activity for human L1CAM. In the case of LCDR3, alanine mutation (D93A) of Asp93 increased the activity, but the mutation of other residues did not (Fig. 1B). We also mutated Val50 in HCDR2 to glutamate, phenylalanine, tyrosine, arginine, or threonine. Because alanine mutation (V50A) of Val50 moderately decreased the activity, the valine residue was speculated to be involved in antigen binding, but to not be optimal for antigen binding. Substitution of glutamate or phenylalanine for valine increased the binding activity for human L1CAM (Fig. 1C). Consequently, we constructed a variant (Ab4M) of Ab4 that contains 3 mutations (V50F in HCDR2, H97A in HCDR3, and D93A in LCDR3) and compared its affinity to that of Ab4 by competitive ELISA. The affinities ($K_d$) of Ab4 and Ab4M for human L1CAM were 130 nM and 2.9 nM, respectively, whereas those of the mutants carrying D93A, H97A, or V50F and H97A were 28 nM, 23 nM, or 16 nM, respectively (Fig. 2A). The results indicate that the affinity of Ab4M for human L1CAM was increased 44-fold compared to that of Ab4 due to the synergistic effect of the 3 critical mutations.

**Epitope mapping and cross-reactivity of affinity-matured antibody (Ab4M)**

For epitope mapping of Ab4M, the antibody was subjected to Western blot analysis using truncated extracellular domains of
human L1CAM fused to human Fc (hFc). Ab4M bound to Ig5, Ig1-5, and Ig1-6, but did not bind to Ig1-4, Ig6, or Fn1-5, indicating that Ab4M binds to Ig5 (Fig. 2B).

To confirm the cross-reactivity of Ab4M with L1CAM from other species, Ab4M was subjected to Western blot analysis using brain tissues from rat, dog, and cynomolgus monkey, as well as recombinant human and mouse L1CAM proteins as positive controls. As shown in Fig. 2C, Ab4M reacted with 2 bands of L1CAM from the tested tissues, consistent with previous reports. In addition, we confirmed the reactivity with mouse and rat L1CAM by flow cytometric analysis using rat PC12 and mouse melanoma B16F1 cells.

**Affinity maturation of Ab4M by yeast display**

Yeast display technology was employed to improve the affinity of Ab4M. First, the scFv form of Ab4M was displayed on the surface of yeast and its antigen-binding activity was measured by flow cytometric analysis using different concentrations of L1CAM (Fig. S1A). Next, 7 residues (amino acids 90-96) in the LCDR3 of Ab4M scFv were randomized to construct a $2 \times 10^9$ sub-library, which was then screened by magnetic activated cell sorting (MACS) with $1 \times 10^{-7}$ M antigen followed by 2 rounds of FACS with $5 \times 10^{-9}$ M antigen. A total of $3 \times 10^7$ colonies were obtained from cell sorting. Finally, 48 clones were recovered and the antigen-binding signal to cell-surface expression signal was analyzed by flow cytometry. One clone with the highest antigen-binding activity was selected (Fig. S1B) and converted into human IgG1 form. This antibody was named Ab417.

**Affinity determination with Ab417**

The affinities ($K_D$) of Ab4, Ab4M, and Ab417 for human and mouse L1CAM were measured by competitive ELISA. The affinities of Ab4, Ab4M, and Ab417 for human L1CAM were $1.3 \times 10^{-7}$ M, $2.9 \times 10^{-9}$ M, and $1.2 \times 10^{-9}$ M, respectively (Fig. 3A), whereas the affinities for mouse L1CAM were $1.7 \times 10^{-9}$ M, $2.2 \times 10^{-10}$ M, and $2.1 \times 10^{-10}$ M, respectively (Fig. 3B). Thus, the affinity of Ab417 for human L1CAM was increased 2.4-fold compared to Ab4M, but the affinity for mouse L1CAM was similar to that of Ab4M. One explanation for this finding is that Ab4 already had a high affinity for mouse L1CAM and the affinity of Ab4M was further increased 7.7-fold compared to Ab4; thus, the high affinities of Ab4M and Ab417 for mouse L1CAM may not have been measured accurately by competitive ELISA because of the limitation of this method.

The antigen-binding kinetics of Ab417 and Ab4M for human and mouse L1CAM were determined using the Octet® RED System (Fig. S2). The affinities ($K_D$) of Ab417 and Ab4M for human L1CAM were 0.24 nM and 0.43 nM, respectively, whereas the affinities for mouse L1CAM were 79.16 pM and 0.14 nM, indicating that the affinities of Ab417 for both human

---

**Figure 1.** Antigen-binding activities of Ab4 mutants for human (black bars) and mouse (gray bars) L1CAM. Each mutant with alanine replacement in the HCDRs (A) or LCDR3 (B) or other mutation at Val50 in the HCDR2 (C) was subjected to indirect ELISA. Relative binding percentage of each mutant compared to Ab4 is shown.
and mouse L1CAM were increased 1.8-fold compared to those of Ab4M (Fig. 3C). The increased affinity of Ab417 compared to Ab4M was due to the slower dissociation rate. The two HCDR residues and changed LCDR3 that contributed to the affinity maturation of Ab4 are presented in the structural model of Ab417 Fv (Fig. 2D). Because the affinities of Ab417 for human and mouse L1CAM are high enough to characterize in vivo profiles, we considered Ab417 as the final candidate for preclinical study.

**Specificity of Ab417**

The antigen-binding specificity of Ab417 was confirmed by indirect ELISA using several truncated domains of human L1CAM. Ab417 bound to Ig5-hFc and Ig1-5-hFc with high affinity but did not bind to Ig1-4-hFc and Ig6-Fn5-hFc (Fig. 4A), demonstrating that Ab417 binds specifically to the Ig5 domain.

The binding specificity of Ab417 was also analyzed using a protein microarray of 384 extracellular, secretory, membrane, and intracellular human proteins (Fig. 4B) with human L1CAM as a positive control. Ab417 reacted with L1CAM but did not bind to any protein in the microarray, suggesting that Ab417 does not have off-target activities.

Next, to examine the normal tissue cross-reactivity of Ab417, we performed immunohistochemistry using 10 types of normal human tissue (cerebellum, adrenal gland, gastrointestinal tract, liver, lung, ovary, pancreas, spleen, thyroid, and uterus) and L1CAM-expressing cholangiocarcinoma cells (SCK)22 as a positive control. The cerebellum and adrenal gland express L1CAM at high and medium levels, respectively, whereas the other tissues do not express L1CAM based on RT-PCR and immunohistochemical analysis. Consistently, Ab417 strongly reacted with the cerebellum and weakly with the adrenal gland but did not react with the other 8 normal tissues (data not shown); however, it bound to L1-CAM expressing peripheral nerves embedded in the tissues, as evidenced in the ovarian tissue (Fig. 4C).

**Single-dose pharmacokinetics of Ab417 in rats**

Because Ab417 binds rat L1CAM, the pharmacokinetic properties of Ab417 were assessed in rats. Antibody was produced from a stable Chinese hamster ovary (CHO) cell line. We produced recombinant rat L1-ECD-S1 and performed Octet kinetics assay to accurately measure the affinity (K_D) of Ab417 for rat L1CAM, which was shown to be 98.4 pM (Fig. S3), similar
to that (79.16 pM) for mouse L1CAM. A single dose of 3 or 10 mg/kg antibody was intravenously (i.v.) injected into 3 male Sprague-Dawley (SD) rats and blood samples were taken at 1, 6, 12, 24, 48, 72, 120, 168, and 240 h. The serum concentrations of the antibody were measured by indirect ELISA using recombinant human L1CAM as a coating antigen. The pharmacokinetic profile and parameters are shown in Fig. 5. The antibody concentration after 3 mg/kg injection declined slightly faster than the concentration after 10 mg/kg injection, and at 240 h the serum concentration was 2.3 and 12.7 μg/mL after 3 and 10 mg/kg injection, respectively. With the 10 mg/kg dose, the area under the plasma concentration-time curve extrapolated to the last sampling point (AUClast), the maximum observed plasma concentration (Cmax), and mean half-life (t1/2) were 8,604.50 ± 1,111.35 μg·h/mL, 204 μg/mL, and 114.49 ± 10.23 h, respectively, whereas the total body clearance (CLt) was 0.94 mL/h/kg. The AUClast, Cmax, and t1/2 increased 2.5, 2.3, and 1.7-fold, respectively, with the 10 mg/kg dose compared to 3 mg/kg, whereas CLt increased little. The data suggest that the CLt of Ab417 comprises an antigen-mediated clearance component and a non-specific clearance component, with a greater contribution of the antigen-mediated clearance component with the 3 mg/kg dose. No general toxicities were observed in the animals.

**In vivo anti-tumor activity of Ab417 in cholangiocarcinoma xenograft nude mouse model**

The anti-tumor efficacy of Ab417 was evaluated in the L1CAM-expressing human cholangiocarcinoma Choi-CK xenograft nude mouse model. The anti-L1CAM chimeric antibody (cA10-A3) we previously developed was included as a reference because it demonstrated tumor growth inhibition in the same xenograft model, but its affinity is 10-fold lower than Ab417 and it lacks cross-reactivity with mouse L1CAM. Ab417 or cA10-A3 at 10 mg/kg or hFc at 3.3 mg/kg was i.v. injected thrice a week into nude mice bearing a Choi-CK xenograft. The tumor volume and body weight of the mice were measured for 3 weeks. At 22 days post-injection, tumor tissues were removed and weighed. The Ab417-treated groups had a mean tumor volume of 320 mm³ (p < 0.01) and tumor weight of 0.219 g (p < 0.05), whereas cA10-A3-treated groups had a mean tumor volume of 722 mm³ and tumor weight of 0.649 g (p < 0.05) (Fig. 6A and 6B). Based on tumor weight, Ab417 resulted in 68.6% tumor growth inhibition compared to hFc without affecting body weight, whereas cA10-A3 resulted in 22.5% tumor growth inhibition. No general toxicities were observed in the control or treated mice, and the mice treated with Ab417 had increased weight compared to those treated with cA10-A3 (Fig. 6C). Thus, the results clearly demonstrate that Ab417 has higher antitumor activity than cA10-A3.

**Discussion**

In this study, we generated a human mAb that cross-reacts with mouse L1CAM using phage display and increased its affinity by site-directed mutagenesis and yeast display. The resulting antibody, Ab417, comprises an antigen-mediated clearance component and a non-specific clearance component, with a greater contribution of the antigen-mediated clearance component with the 3 mg/kg dose. No general toxicities were observed in the animals.
In addition, Ab417 has advantages over previous anti-L1CAM mAbs due to high affinity, better therapeutic efficacy, and cross-reactivity with rodent L1CAM, which may facilitate its preclinical and clinical development.

Epitope mapping experiments revealed that Ab417 binds to the Ig5 domain of L1CAM. Because Ab417 cross-reacts with L1CAM from mouse, rat, dog, and cynomolgus monkey, its epitope sequence may be evolutionarily conserved. Murine anti-L1CAM mAbs generated by immunizing mice with human L1CAM protein have been shown to recognize the Ig1, Ig3, or Fn4 domain, but a mAb binding the Ig5 domain has not been reported. This may be due to higher sequence homology (92%) of Ig5 between humans and mice, compared to sequence homology (88%) of entire L1CAM sequence. This study demonstrates the advantages of phage display technology in generating rodent-cross-reactive antibodies. To our knowledge, Ab417 is the only mAb specific to the Ig5 of L1CAM.

Studies on the functions of L1CAM have shown that the Ig1–4 domains mediate homophilic interactions with other L1CAM in trans and enhanced proliferation of cancer cells by activating ERK1/2 signaling, whereas an Ig6 domain-containing RGD motif bound to integrins and enhanced cell motility and invasiveness via the NF-κB signaling pathway. However, the function of the Ig5 domain is unknown. Ab417 did not inhibit the proliferation of tumor cells in vitro, but it exhibited excellent tumor growth inhibition in vivo. The same phenomenon was observed in another study with anti-L1CAM mAb recognizing the Ig1 domain and inhibiting tumor growth in ovarian carcinoma xenograft nude mouse models. The mode of action of Ab417 will be elucidated in a future study.

L1CAM expression in the peripheral nerves and kidney tubules raises concerns that anti-L1CAM mAb may induce toxicity. In this study, Ab417 did not induce any adverse effect in the pharmacokinetics and efficacy studies. In addition, when Ab417 (30 μg/mL) was directly added to human neural progenitor cells, ReNcell VM, it did not affect the cells (data not shown). A repeated-dose toxicological study of Ab417 in cynomolgus monkeys remains to be conducted to predict potential toxicity in humans.

**Figure 4.** Specificity of Ab417. (A) Epitope of Ab417 was confirmed by indirect ELISA using Ig1-4, Ig1-5, Ig5, and Ig6 through Fn1-5 (Ig6-Fn5). (B) Off-target activity of Ab417 was analyzed using UNichip® AV-400 protein microarray with human L1CAM used as a positive control. Ab417 bound to the L1CAM up to the signal intensity of 154% (white arrow) with no off-target activity. Red circle indicates the secondary antibody control. (C) Normal tissue cross-reactivity of Ab417 or human IgG as a negative control was analyzed by immunohistochemistry using 10 types of human normal tissues and L1CAM-expressing tumor cells (SCK) as a positive control. Ab417 bound to the SCK cells and the cerebellum that was reported to express L1CAM but did not bind to other tissues (for example, ovary and uterus). The arrow in the ovary sample indicates the peripheral nerves stained by Ab417.
In summary, we successfully developed a high affinity human anti-L1CAM mAb (Ab417) that cross-reacts with rodent L1CAM using phage display and yeast display technologies in combination with site-directed mutagenesis. Ab417 had a long serum half-life in rats and good anti-tumor efficacy in a cholangiocarcinoma xenograft nude mouse model. No general toxicities were observed in the in vivo studies. Therefore, Ab417 may have potential as a therapeutic agent for the treatment of cholangiocarcinoma and other types of L1CAM-positive cancers.

Materials and methods

Cell lines and cell culture

HEK293T, Choi-CK, SCK, PC12, and B16F1 cells were grown at 5% CO₂, 37°C in DMEM (Welgene, Republic of Korea) supplemented with 10% FBS (Atlas). CHO-DG44 cells were grown at 5% CO₂, 37°C in MEM-α (Welgene) supplemented with 5% (v/v) dialyzed FBS (Gibco).

Selection of Fabs binding to human and mouse L1CAM from a phage antibody library

Human combinatorial naïve Fab library was constructed as described previously. For preparation of the panning antigens, the extracellular domain (ECD) of human L1CAM (hL1-ECD) was expressed in HEK293T cells and purified from the culture supernatant by affinity chromatography on a protein A-sepharose column (Millipore) conjugated with anti-L1CAM mAb, A10-A3. Also, the ECD (mL1-ECD-S1) of mouse L1CAM fused to the preS1 tag at its C-terminus was expressed and purified by affinity chromatography on a sepharose column conjugated with anti-preS1 mAb, KR127, as described previously. Phage-displayed human naïve Fab library was prepared using VCSM13 helper phages and panned against hL1-ECD for the first and second rounds followed by mL1-ECD-S1 for the third round, using the standard protocols. After panning, E. coli TG1 cells were infected with the eluted phages and cultured in 2xYT medium (2 × YTA) containing ampicillin overnight. Total 125 colonies were chosen randomly, separately inoculated into 2xYT media and incubated at 37°C until the OD600 reached to 0.7. Subsequently, 1 mM IPTG was added to the culture and expression of soluble Fab fused to Protein III was induced at 30°C overnight. The culture supernatant was subjected to indirect ELISA, quantitative ELISA, and competitive ELISA to select high-affinity clones for both human and mouse L1CAM.

Conversion of Fabs into IgG1 format and expression of IgG1

To convert the selected Fabs into whole IgG1, the human VH and Vκ sequences were amplified by PCR and

Figure 5. Pharmacokinetics of Ab417 in SD rats. (A) Serum concentration of Ab417 relative to time profiles after single intravenous administration. Concentration of antibodies in rat plasma was assessed by indirect ELISA against human L1CAM. Each bar represents the mean ± SD, n = 3. (B) Mean data of PK parameters. SD, standard deviation; AUCₘₐₓ, the area under the plasma concentration-time curve extrapolated to the last sampling point; Cₘₐₓ, the maximum observed plasma concentration; Tₘₐₓ, the time of occurrence of Cₘₐₓ; t₁/₂, the apparent terminal half-life; CLt, total body clearance; MRT, mean residence time; and Vd, distribution volume.
combined with the leader sequences of IgG heavy and light chains, respectively, by recombinant PCR. The resulting VH and Vk were sequentially subcloned into the EcoRI-ApaI and HindIII-BsiWI sites, respectively, in the expression plasmid (pCMV-dhfr) containing the human Cγ1 and Cκ gene.53 The IgG1 expression plasmid was introduced into HEK293T cells using polyethylenimine (Polysciences) according to the Cold Spring Harbor Protocols, and the transfected cells were cultured in protein-free medium (CD293, Invitrogen or Pro-293a CDM, Lonza). The culture supernatant was centrifuged and filtered using a bottle top filter (0.22 μm PES, Sartorius), and then subjected to quantitative ELISA and indirect ELISA to analyze antigen binding affinity. IgG1 was purified from the culture supernatant by affinity chromatography on a protein A-agarose (Millipore), and the protein concentration was determined with a NanoDrop (Thermo Scientific).

**ELISAs**

Indirect ELISA was carried out using hL1-ECD-S1 or mL1-ECD-S1 (100 ng/well) as a coating antigen, as described previously.31 For competitive ELISA, 0.1% PBA (PBS containing 0.1% BSA) solution containing antibody (1.5–5.9 μg/mL) and various concentrations (10^{-11}–10^{-6} M) of hL1-ECD-S1 or mL1-ECD-S1 as a competing antigen were pre-incubated at 37°C for 3 h. The mixture was then added to each well, which had been coated with 100 ng of hL1-ECD-S1 or mL1-ECD-S1. Bound antibody was detected by indirect ELISA. Affinity was determined as the antigen concentration required to inhibit 50% of binding activity and K_D value was calculated from a Klotz plot.

**Western blot analysis**

For epitope mapping of Ab4M, hL1-ECD and its truncated domains fused to hFc were expressed in HEK293T cells and the culture supernatant containing 5 μg of each protein sample was reduced and subjected to quantitative ELISA and indirect ELISA to analyze antigen binding affinity. IgG1 was purified from the culture supernatant by affinity chromatography on a protein A-agarose (Millipore), and the protein concentration was determined with a NanoDrop (Thermo Scientific).

![Figure 6. Anti-tumor efficacy of Ab417 in comparison with cA10-A3 in Choi-CK cholangiocarcinoma xenograft model. Ab417, cA10-A3, or hFc as an isotype control was i.v. injected into nude mice (n=10 per group) thrice a week for 21 days. Mean tumor volume (A), tumor weight (B), and body weight (C) are shown. Each point represents the mean ± SD; bars, SD; *p < 0.05, **p < 0.01, significant difference from the isotype control group by Dunnett’s t-test. (D) Photographs of the resected tumors at the end of experiment.](image-url)
β-Actin mAb (1:1,000, Cell Signaling) and goat anti-rabbit IgG-HRP (1:5,000, Santa Cruz Biotechnology).

**Flow cytometry**

B16F1 or PC12 cells (2 × 10^5) were incubated with Ab417 or human IgG (Thermo Scientific) as a negative control at 4°C for 1 h. After washing twice with 0.1% PBA, the cells were incubated with anti-human IgG (Fc-specific)-FITC (Sigma Aldrich) at 4°C for 1 h. Propidium iodide-negative cells was analyzed for antibody binding using FACSCalibur (Becton Dickinson), and data was analyzed by WinMDI ver. 2.9.

**Affinity determination of antibody by octet red system**

Anti-hFc sensor (AHC, ForteBio) was first soaked in 0.1% PBA for 20 min, antibody (0.2 mL of 2 μg/mL) was captured for 10 min, and then washed in 0.1% PBA for 2 min. Purified hL1-ECD (100, 50, 25, 12.5 and 6.25 nM) and mL1-ECD-S1 (30, 10, 3.3, and 1.1 nM) were prepared as a serial dilution in PBA and incubated with antibody bound on the chips. Association and dissociation rates were measured for 15 and 30 min, respectively. All measurements were corrected for baseline drift by subtracting a control sensor (antibody-captured AHC sensor) exposed to running buffer only. Operating temperature was maintained at 30°C, and data were analyzed by WinMDI ver. 2.9.

**Affinity maturation of Ab4M by yeast display**

The gene encoding the Ab4M scFv was synthesized by PCR and subcloned into pYD1 plasmid (Invitrogen) to yield pYD1-scAb4M. This plasmid was introduced into yeast strain, EBY100. Display of the scFv on the surface of yeast cells and its antigen-binding activity were measured by flow cytometric analysis using different concentrations (10^-5–10^-8 M) of Ig5-hFc. Seven residues in the LCDR3 of Ab4M were randomized and selected from Lonza (OCT) compounds. The template fragments along the CDRs to the FR templates, 5 residues on either side of the CDR were included in the CDR template. An alignment of the fragments was generated based on overlapping segments and a structural sequence alignment. The template fragments along with the alignment were processed by MODELLER (Accelrys). This protocol creates conformational restraints derived from the set of aligned structural templates. An ensemble of structures that satisfy the restraints were created by simulated annealing and conjugate gradient optimization procedures. One or more model structures were selected from this ensemble on the basis of an energy score, derived from the score of the quality of the protein structure and satisfaction of the conformational restraints. The models were inspected and the side chains of the positions which differ between the target and template were optimized using a side chain optimization algorithm and energy minimized. A suite of visualization and computational tools were used to assess the conformational variability of the CDRs, as well as the core and local packing of the domains and regions and a surface analysis to select one or more preferred models.

**Construction of stable CHO cell line and production of Ab417**

For large scale production of Ab417, the gene encoding the heavy or light chain was codon-optimized for mammalian cell expression and subcloned into the EcoRI-NotI or HindIII-XbaI site of pdCMV-dhfrC, respectively, to yield pdCMV-dhfrC-Ab417. This expression plasmid was introduced into CHO-DG44 cells, and stably transfected cell lines were selected in a medium containing G418 (550 μg/mL). A subclone (#9) was adapted to 20 nM methotrexate (Sigma Aldrich) for gene amplification, and survived cells (#9-20) were grown in serum-free medium (SFM4CHO, Thermo Scientific). The culture supernatant was subjected to affinity chromatography on a protein A-agarose for purification, as described previously.

**Off-target activity assay**

UNichip® Av-400 microarray (PROTAGEN, Germany) was blocked with 2% BSA in TBST (2% BSA/TBST) at room temperature and incubated with 0.05 μM Ab417, followed by goat anti-human IgG F(ab)2-Cy3 (Protagen) in 2% BSA/TBST. Read out of the results was performed with a confocal microarray reader (ScanArray 4000, Perkin Elmer Life Science).

**Immunohistochemistry**

Reactivity of Ab417 to normal human tissues was assessed by Reference Bio Laboratories Inc.. Tissue sections of 6 μm thickness were cut and embedded in optimal cutting temperature (OCT) compounds. Sections were stained using avidin-biotin complex, as described previously. After cell sorting, 3 × 10^3 cells were obtained and 48 viable colonies were subjected to DNA sequencing to determine their VH and VL sequences.

**Modeling of the 3-dimensional structure of Ab417**

Structural models of Ab417 Fv were generated using Lonza’s modeling platform. Candidate structural template fragments for the framework and CDRs as well as the full Fv were scored, ranked and selected from Lonza’s antibody database based on their sequence identity to the target. In order to structurally align
culture supernatant of the recombinant CHO-DG44 cell line (#9-20) as described above. Ab417 at a dose of 3 or 10 mg/kg was i.v. injected into 3 rats. After indicated time points, blood was collected from the rats and serum was recovered. To determine the serum concentration of Ab417, the sera were subjected to indirect ELISA using hL1-ECD-S1 as a coating antigen. Serum concentrations were determined from standard curves that were generated from known concentrations of purified Ab417. PK parameters (AUC_cl, C_max, T_max, t_1/2, CL, Vd, and MRT) were calculated using Phoenix WinNonlin (ver. 6.2, Phasight-A Vertara Company, USA).

In vivo antitumor activity of Ab417

Nude mice (BALB/c Slc- nu, 5 weeks old) were obtained from Japan SLC, Inc. (Japan). Choi-Ck cells (1 × 10⁶) were inoculated subcutaneously into the right flank of each mouse. Constructed Choi-Ck tumor tissue (3 × 3 × 3 mm³) was inoculated subcutaneously into the back of mice. When tumor volume reached to 100 mm³ (n = 10 per group), antibody at a dose of 10 mg/kg was i.v. injected three times per week for 3 weeks. Ab417 and cA10-A3 were produced from the recombinant CHO-DG44 cell lines secreting either antibody.

Tumor growth was monitored by measuring the length and width of the tumor with a caliper and calculating tumor volume on the basis of the following formula; TV (mm³) = L (mm) × W² (mm²) × 1/2, where L is length and W is width. Body weight of the animals was measured twice a week. At the end of the experiments, mice were euthanized. Tumor tissues were taken out and weighed. Tumor growth inhibition rate (IR) was calculated as following formula; IR (%) = (1 - T/C) × 100, where T is mean tumor weight of the test substance group and C is mean tumor weight of the negative control group.

Statistical analysis

Data are presented as mean ± SD and statistical comparisons between groups were performed using one-way analysis of variance (ANOVA) followed by Dunnett’s t-test or Steel’s test. A value of p < 0.05 was considered significant.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

This research was supported by a grant (C1007150-01-01) from the Ministry of Science and Technology of Korea and a grant (KDDF-201212-12) from the Korea Drug Development Fund (KDDF) funded by Ministry of Science, ICT and Future Planning, Ministry of Trade, Industry & Energy and Ministry of Health & Welfare, and 2015 Research Grant from Kang won National University(No. 520150322).

References

1. Haspel J, Grumet M. The L1CAM extracellular region: a multi-domain protein with modular and cooperative binding modes. Front Biosci 2003; 8:s1210-25; PMID:12957823; http://dx.doi.org/10.2741/1108
2. Rathjen FG, Schachner M. Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J 1984; 3:1-10; PMID:6368220
3. Pancook JD, Reisfeld RA, Variki N, Vitiello A, Fox RI, Montgomery AM. Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. J Immunol 1997; 158:4413-21; PMID:9127006
4. Debiec H, Christensen EL, Ronco PM. The cell adhesion molecule L1 is developmentally regulated in the renal epithelium and is involved in kidney branching morphogenesis. J Cell Biol 1998; 143:2067-79; PMID:9864376; http://dx.doi.org/10.1083/jcb.143.7.2067
5. Thor G, Probstmeier R, Schachner M. Characterization of the cell adhesion molecules L1, N-CAM and J1 in the mouse intestine. EMBO J 1987; 6:2581-6; PMID:3315649
6. Raveh S, Gavert N, Ben-Ze’ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett 2009; 282:137-45; PMID:19144458; http://dx.doi.org/10.1016/j.canlet.2008.12.021
7. Kiefel H, Bondong S, Erbe-Hoffmann N, Hazin J, Riedel S, Wolf J, Pfeifer M, Arlt A, Schäfer H, Miekenösters S, et al. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IκBα expression. Oncogene 2010; 29:4766-78; PMID:20543863; http://dx.doi.org/10.1038/onc.2010.230
8. Kiefel H, Bondong S, Pfeifer M, Schirmer U, Erbe-Hoffmann N, Schäfer H, Hebens S, Altevogt P. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation. Carcinogenesis 2012; 33:1919-29; PMID:22764136; http://dx.doi.org/10.1039/c2can2220
9. Hall H, Walsh FS, Doherty P. Review: a role for the FGF receptor in the axonal growth response stimulated by cell adhesion molecules? Cell Adhes Commun 1996; 3:441-50; PMID:8807188; http://dx.doi.org/10.1006/cell.1996.0012
10. Donier E, Gomez-Sanchez JA, Grijota-Martinez C, Lakoma J, Baars S, Garcia-Alonso L, Cabedo H. L1CAM binds ErbB receptors through Ig-like domains coupling cell adhesion and neuroregulin signalling. PLoS One 2012; 7:e40674; PMID:22815787; http://dx.doi.org/10.1371/journal.pone.0040674
11. Gouveia RM, Gomes CM, Sousa M, Alves PM, Costa J. Kinetic analysis of L1 homophilic interaction: role of the first four immunoglobulin domains and implications on binding mechanism. J Biol Chem 2008; 283:28038-47; PMID:18701456; http://dx.doi.org/10.1074/jbc.M804991200
12. Haspel J, Friedlander DR, Ivy-May N, Chickramane S, Roonapru C, Chen S, Schachner M, Grumet M. Critical and optimal Ig domains for promotion of neurite outgrowth by L1/Ng-CAM. J Neurobiol 2000; 42:287-302; PMID:10645969; http://dx.doi.org/10.1002/(SICI)1097-4699(20000215)42:3<287::AID-NJCB2252>3.0.CO;2-X
13. Yip PM, Zhao X, Montgomery AM, Siu CH. The Arg-Gly-Asp motif in the cell adhesion molecule L1 promotes neurite outgrowth via interaction with the alphabeta3 integrin. Mol Biol Cell 1998; 9:277-90; PMID:9450954; http://dx.doi.org/10.1091/mbc.9.2.277
14. Kulahin N, Li S, Hinsby A, Kiselyov V, Bock E. Fibronectin type III (FN3) modules of the neuronal cell adhesion molecule L1 interact directly with the fibroblast growth factor (FGF) receptor. Mol Cell Neurosci 2008; 37:528-36; PMID:18222703; http://dx.doi.org/10.1016/j.mcn.2007.12.001
15. Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery AM. Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem 2004; 279:28880-8; PMID:15128735; http://dx.doi.org/10.1074/jbc.M40075200
16. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Braitl T, Ben-Ze’ev A, L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168:633-42; PMID:15716380; http://dx.doi.org/10.1083/jcb.200408051
17. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, et al. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer
20. Sebens Muerkoster S, Werbing V, Sipos B, Debus MA, Witt M, Gross-19. Jung J, Son YS, Park H, Jeon SK, Lee JW, Choi SY, Kim JM, Kwon YG,-18. Min JK, Kim JM, Li S, Lee JW, Yoon H, Ryu CJ, Jeon SH, Lee JH, Kim JY,-23. Magrini E, Villa A, Angiolini F, Doni A, Mazzarol G, Rudini N, Madi-
22. Yoon H, Min JK, Lee DG, Kim DG, Koh SS, Hong HJ. L1 cell adhesion
29. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grun-
28. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro
26. Smith IE. Trastuzumab for early breast cancer. Lancet 2006; 367:107;
42. Choi SY, Jo YS, Huang SM, Liang ZL, Min JK, Hong HJ, Kim JM. L1
40. Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular
44. Weidle UH, Dieckmann C, Korniienko O, Moldenhauer G, Kiefel H,
45. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski
46. Schafer H, Dieckmann C, Korniienko O, Moldenhauer G, Kiefel H,
39. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Marava-
38. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholan-
37. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making anti-
36. Bradbury AR, Sidhu S, Dubel S, McCafferty J. Beyond natural anti-
35. Zhou H, Zhang YL, Lu G, Ji H, Rodi CP. Recombinant antibody 
34. Wei CH, Lee ES, Jeon JY, Heo YS, Kim SJ, Jeon YH, Kim KH, Hong 
33. Winter G, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348:552-4; PMID:2247164; http://dx.doi.org/10.1038/348552a
51. Oh MS, Kim KS, Jang YK, Maeng CY, Min SH, Jang MH, Yoon SO, Kim JH, Hong HJ. A new epitope tag from hepatitis B virus preS1 for immunodetection, localization and affinity purification of recombinant proteins. J Immunol Methods 2003; 283:77-89; PMID:14659901; http://dx.doi.org/10.1016/j.jim.2003.08.010

52. Coomber DW. Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol 2002; 178:133-45; PMID:11968482

53. Yoon SO, Lee TS, Kim SJ, Jang MH, Kang YJ, Park JH, Kim KS, Lee HS, Ryu CJ, Gonzales NR, et al. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J Biol Chem 2006; 281:6985-92; PMID:16407221; http://dx.doi.org/10.1074/jbc.M511165200

54. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 2004; 340:1073-93; PMID:15236968; http://dx.doi.org/10.1016/j.jmb.2004.05.051